290992
Last Update Posted: 2009-03-30
Recruiting has ended
All Genders accepted | Under 17 Years |
30 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Rasburicase for Hyperuricemia
Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration.
Secondary: To investigate the safety in this population and anti-SR29142 antibodies, anti-SCP antibodies, and pharmacokinetic parameters.
Eligibility
Relevant conditions:
Nutritional and Metabolic Diseases
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov